# Phase 3b Study to Evaluate Skeletal Response to Eliglustat in Adult Patients Who Completed Phase 2 or Phase 3 Studies

> **NCT02536755** · PHASE3 · COMPLETED · sponsor: **Genzyme, a Sanofi Company** · enrollment: 31 (actual)

## Conditions studied

- Gaucher Disease

## Interventions

- **DRUG:** Eliglustat, GZ385660

## Key facts

- **NCT ID:** NCT02536755
- **Lead sponsor:** Genzyme, a Sanofi Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-10-27
- **Primary completion:** 2021-06-24
- **Final completion:** 2021-06-24
- **Target enrollment:** 31 (ACTUAL)
- **Last updated:** 2022-07-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02536755

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02536755, "Phase 3b Study to Evaluate Skeletal Response to Eliglustat in Adult Patients Who Completed Phase 2 or Phase 3 Studies". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT02536755. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*